TACE.PVE.HIFU序贯治疗原发性肝癌疗效评价.doc

TACE.PVE.HIFU序贯治疗原发性肝癌疗效评价【摘要】 目的 研究TACE.PVE.HIFU序贯治疗原发性肝癌临床疗效及方法。方法 将我院60例原发性肝癌患者随机分为两组:治疗组30例:TACE.PVE.HIFU序贯治疗;对照组30例:给予经导管化疗栓塞术(TACE)。两组患者治疗后对其临床疗效进行评价分析,所有患者随访3年观察生存情况,并分析相关因素。结果 60例原发性肝癌患者,治疗组总有效率为16例占53.3%,而对照组7例占23.3%,治疗组治疗后临床疗效明显要好于对照组。两组原发性肝癌患者治疗后,其治疗组3年生存率为14例占46.7%,而对照组8例占26.7%,治疗组生存率明显高与对照组。60例原发性肝癌不同肝功能Child分级患者治疗后:6个月生存率51例占85.0%、1年生存率43例占71.7%、2年生存率32例占53.3%、3年生存率22例占36.7%。肝功能Child A生存率较高。结论 TACE.PVE.HIFU序贯治疗在原发性肝癌应用互为补充,最终达到彻底杀灭癌细胞的目的。? 【关键词】 原发性肝癌;TACE;PVE;HIFU;疗效评价;生存率?? TACE.PVE.HIFU sequential evaluation of the treatment of primary liver cancer GUO Yin-mou.Tumor branch Henan Province Shangqiu first People’s Hospital Henan,Shangqiu 476000,China 【Abstract】 Objective To study TACE.PVE.HIFU clinical efficacy of sequential treatment of primary liver cancer and methods. Methods 60 patients with primary liver cancer in our hospital were randomly divided into two groups: treatment group 30: TACE.PVE.HIFU sequential therapy; control group, 30 cases: give transcatheter chemoembolization (TACE). After treatment, to evaluate the clinical efficacy analysis, all patients were followed up for 3 years observation of survival, and analysis of relevant factors. Results 60 patients with primary liver cancer, total effective rate was 53.3% in 16 cases, 7 cases of the control group, 23.3% clinical efficacy in treatment group significantly better than the control group. Two groups of patients with primary liver cancer, its treatment of 3-year survival rate was 46.7% for the 14 cases, while 8 patients accounted for 26.7%, significantly higher survival rate in treatment group and control group. 60 cases of primary liver cancer patients with different grades of liver function after treatment Child: 6-month survival rate of 85.0% in 51 cases, 43 patients 1 year survival rate of 71.7%, 2-year survival rate of 32 cases of 53.3%, 3 years 36.7% survival rate of 22 cases. Child A liver function have a higher survival rate. Conclusion TACE.PVE.HIFU sequential treat